BLCO / Bausch + Lomb Targets $788 Million IPO

Bausch + Lomb Corporation (NYSE:BLCO ) Q3 2023 Earnings Conference Call November 1, 2023 8:00 AM ET Company Participants George Gadkowski - Vice Presi more_horizontal

Investors need to pay close attention to Bausch + Lomb (BLCO) stock based on the movements in the options market lately. more_horizontal

Bausch + Lomb (BLCO) came out with quarterly earnings of $0.18 per share, beating the Zacks Consensus Estimate of $0.16 per share. This compares to ea more_horizontal

Investors interested in Medical Services stocks are likely familiar with Bausch + Lomb (BLCO) and Doximity (DOCS). But which of these two stocks is mo more_horizontal

Bausch + Lomb (BLCO) came out with quarterly earnings of $0.10 per share, missing the Zacks Consensus Estimate of $0.14 per share. This compares to ea more_horizontal

Brent Saunders led Bausch + Lomb Corporation when it was sold to Valeant Pharmaceuticals. He later led and sold competitor Allergan to AbbVie. more_horizontal

Bausch + Lomb Corporation (NYSE:BLCO ) Q4 2022 Earnings Conference Call February 22, 2023 8:00 AM ET Company Participants Art Shannon – Investor Rel more_horizontal

Bausch + Lomb Corp. BLCO, -2.01% said Wednesday it had a loss of $1 million, or breakeven on a per-share basis, for the fourth quarter, after earnings more_horizontal